Alumis Inc., a clinical-stage biopharmaceutical company, announced key developments in its pipeline and a merger with ACELYRIN during its recent financial results release. At the AAD 2025 conference, ...
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
BriaCell (BCTX) Therapeutics presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium, SABCS, taking place December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback